A recent study (I Weinstein-Nakar et al. Clin Gastroenterol Hepatol 2018; 16: 1089-97, editorial 1037-39)) provide data from 151 children who underwent multiple modalities to assess their Crohn’s disease (CD) (ImageKids Study group).
Key findings:
- MRE and ileocolonoscopy had concordance in 69% of cases. 55% had neither transmural nor mucosal healing, 14% had both transmural and mucosal healing.
- MRE did not show features of active disease in 25% that was identified on ileocolonoscopy. This is an expected finding given the ability of endoscopy (& capsule endoscopy) to identify milder mucosal lesions more precisely.
- MRE did show evidence of disease in 6% who had unremarkable ileocolonoscopy (mucosal healing)
- Calprotectin at a cut-off of 100 mcg/mL had 71% sensitivity and 92% specificity for diagnosing mucosal and transmural healing whereas a level of 300 mcg/mL had a sensitivity of 80% and specificity of 81%.
My take: This study confirms the complementary nature of cross-sectional imaging with endoscopy to determine healing. In addition, in children with CD, calprotectin levels of more than 100 mcg/mL could indicate the need for further assessment (if this would affect management).
This is in agreement with another recent post: IBD Reviews: Antibiotics and Biomarkers: “a calprotectin has a high level of excluding active inflammation/IBD. In populations with IBD, levels more than 250 mcg/g indicate a high likelihood of active inflammation whereas levels between 100-250 are indeterminate.”
Related blog posts:
- Capsule endoscopy more sensitive than MRE
- MRE Does Not Fare Well at Detecting Lesions Evident on Upper Endoscopy
- Magnetic resonance enterography for Crohn’s disease
- Best Fecal Marker for Crohn’s disease
- How sensitive is Calprotectin?
- Fecal Calprotectin Monitoring Helpful at Identifying Relapse in IBD | gutsandgrowth
- Biomarkers identify patients who benefit and how
- Prospective Monitoring of Calprotectin for Crohn’s Disease
- Value of Calprotectin | gutsandgrowth
